Journal Information
Vol. 44. Issue 7.
Pages 393-395 (January 2008)
Share
Share
Download PDF
More article options
Vol. 44. Issue 7.
Pages 393-395 (January 2008)
Case Report
Full text access
Etanercept as a Possible Trigger of Fatal Pulmonary Fibrosis
Visits
4846
Juan M. Díez Piñaa,
Corresponding author
jmdpas@hotmail.com

Correspondence: Dr J.M. Díez Piña C/Palo de Rosa, 3, escalera 3,7 A 28005 Madrid, Spain
, Óscar Vázquez Gómezb, Sagrario Mayoralas Alisesa, José D. García Jiméneza, Dolores Álvaro Álvareza, M. Paz Rodríguez Boladoa
a Servicio de Neumología, Hospital de Móstoles, Móstoles, Madrid, Spain
b Servicio de Medicina Interna, Hospital de Mostoles, Móstoles, Madrid, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Pulmonary fibrosis can be caused by external agents, including certain drugs. For some time now, tumor necrosis factor antagonists such as etanercept have been used to treat certain autoimmune diseases. Fibrosis caused by medication responds to withdrawal of the drug and treatment with corticosteroids. Very rarely, fibrosis is irreversible. We present the case of a patient who developed pulmonary fibrosis after initiating treatment with etanercept. The clinical course was fulminant despite withdrawal of the drug and high doses of corticosteroids.

La fibrosis pulmonar es una enfermedad que puede estar causada por agentes externos como determinados fármacos. Desde hace un tiempo se utilizan fármacos antagonistas del factor de necrosis tumoral (TNF) para ciertas enfermedades autoinmunitarias, siendo un ejemplo de estos fármacos el etanercept. Las fibrosis secundarias a medicamentos se caracterizan por la respuesta a la retirada del fármaco y a esteroides. En muy raras ocasiones se produce una fibrosis irreversible. Presentamos el caso de un paciente que desarrollo una fibrosis pulmonar tras iniciar tratamiento con etanercept y que tuvo un curso clinico nefasto a pesar de la retirada del anti-TNF y dosis altas de esteroides.

Key words:
Etanercept
Pulmonary fibrosis
Tumor necrosis factor
Full text is only aviable in PDF
References
[1]
CA Dinarello.
Differences between anti-TNF-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
J Rheumatol, 32 (2005), pp. 40-47
[2]
A Gottlieb, CH Antoni.
Treating psoriatic arthritis: how effective are TNF antagonists?.
Arthritis Res Ther, 6 (2004), pp. 31-35
[3]
B Haraoui.
Differentiating the efficacy of TNF inhibitors.
J Rheumatol, 32 (2005), pp. 3-7
[4]
B Scallon, A Cai, N Solowski, B Germain, A Laffon, J Jacobs, et al.
Binding and functional comparisons of two types of tumor necrosis factor antagonists.
J Pharmacol Exp Ther, 301 (2002), pp. 418-426
[5]
EC Keystone.
Safety of biologic therapies — an update.
J Rheumatol, 32 (2005), pp. 8-12
[6]
H Liote.
Respiratory complications of new treatments for rheumatoid artritis.
Rev Mal Respir, 21 (2004), pp. 1107-1115
[7]
L Peno-Green, G Lluberas, T Kingsley, S Brantley.
Lung injury linked to etanercept therapy.
Chest, 122 (2002), pp. 1858-1860
[8]
D Smith, S Letendre.
Viral pneumonia as a serious complication of etanercept therapy.
Ann Intern Med, 136 (2002), pp. 174
[9]
T Tokunaga, S Ohno, S Tajima, K Oshikawa, M Hironaka, Y Sugiyama.
Usual interstitial pneumonia associated with psoriasis vulgaris [in Japanese].
Nihon Kokyuki Gakkai Zasshi, 40 (2002), pp. 692-696
[10]
K Kawakami, J Kadota, K Abe, K Iida, M Kaseda, S Kawamoto, et al.
A case of non-specific interstitial pneumonia associated with psoriasis vulgaris and polymyalgia rheumatica [in Japanese].
Nihon Kyobu Shikkan Gakkai Zasshi, 35 (1997), pp. 1395-1399
[11]
F Ohyanagi, Y Ando, F Nagashima, M Narabayashi, Y Sasaki.
Acute gefitinib-induced pneumonitis.
Int J Clin Oncol, 9 (2004), pp. 406-409
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?